PTC Therapeutics

PTCT · NASDAQ

$62.92+$1.39 (+2.26%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $61.53

PTCT analyst rating

BuyConsensus of 14 analysts over the last 12 months. 79% rate it a buy.

Strong buy0
Buy11
Hold2
Underperform0
Sell1

12-month price target · 16 analysts

Average $104.67 (+66.4% upside)

Low: $70.70
Now: $62.92
High: $143.85

Upgrades and downgrades

The latest rating actions, newest first

PTCT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 15, 2026	Initiates	Buy	$80.00 → $90.00	100%
RBC Capital	Oct 8, 2026	Maintains	Sector Perform	$85.00 → $75.00	44%
Cantor Fitzgerald	Sep 22, 2026	Maintains	Overweight	$130.00 → $137.00	41%
Leerink Partners	Sep 14, 2026	Initiates	Outperform	$98.00	—
Barclays	Aug 14, 2026	Maintains	Overweight	$120.00 → $122.00	45%
Wells Fargo	Aug 13, 2026	Maintains	Overweight	$106.00 → $109.00	29%
Morgan Stanley	Jul 31, 2026	Maintains	Overweight	$93.00 → $104.00	49%
Wells Fargo	Jul 31, 2026	Maintains	Overweight	$93.00 → $106.00	29%
Wells Fargo	Jul 20, 2026	Maintains	Overweight	$95.00 → $93.00	29%
Cantor Fitzgerald	Jul 16, 2026	Maintains	Overweight	$124.00 → $130.00	41%

The case for and against

Updated Oct 17, 2026

Bull case

PTC Therapeutics is supported by a strong commercial base from Sephience, which launched in 2025 and has already outperformed internal projections and investor expectations, with $124.6M in revenue and over 90% of U.S. centers of excellence having prescribed it as of 1Q26. The company also has meaningful incremental upside from ST-920 in Fabry disease, acquired for $111M upfront plus up to $100M contingent on regulatory milestones, backed by favorable 52-week renal data and a large ~11,000-patient U.S. addressable population. Beyond that, votoplam adds further optionality through positive Phase 2 data, while PTC’s broader rare-disease pipeline, global expansion plans to more than 30 countries by end-of-2026, and evidence of durable switching and low double-digit discontinuations support a longer growth runway.

Bear case

PTC Therapeutics is weighed down by heavy dependence on a narrow set of rare-disease launches, making its revenue base vulnerable if Sephience underperforms, Translarna weakens after the European Marketing Authorization withdrawal, or Emflaza and DMD products miss guidance. The company also faces elevated clinical, regulatory, and reimbursement risk because rare-disease enrollment delays can materially push out sales, AAV gene therapy still has limited U.S. approval history, and payors may resist some of the most expensive treatments. Even where the pipeline has promise, the market is already assuming meaningful value from Sephience and votoplam, so any slower uptake, development setback, or commercial shortfall could force a sharp reassessment of the stock’s fundamentals.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.